It’s Flu Season.

Please view our Flu Visitation Guidelines before you visit.

105 results
Page of 9
  • HW-004 DT

    A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System (VAS) for Destination Therapy of Advanced Heart Failure

    Type: Device Trial

    Trial is not open for enrollment.

    Prinical Investigator: Mark Zucker, MD, JD

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • Ixmyelocel-T and Dilated Cardiomyopathy (STEM Cell)

    Aastrom - A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of transendocardial injection of ixmyelocel-T in subjects with heart failure due to ischemic dilated cardiomyopathy [PROTOCOL NUMBER: 55-1202-1]

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • Tafamidis Meglumine (PF-06291826) Protocol # B3461028

    Pfizer, Inc. - A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • ALN-TTRSC-004

    Alnylam Pharmaceuticals, Inc. - A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • HeartMate 3/ MOMENTUM 3

    Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3™

    Type: Device Trial

    Open for Enrollement

    Principal Investigator: Margarita Camacho, MD

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • The PARTNER II Trial with Registries

    Edwards Lifesciences, LLC -The Safety and Effectiveness of the SAPIEN XT™ Transcatheter Heart Valve with NovaFlex and Ascendra delivery systems in Intermediate and High Risk for Aortic Valve Surgery and Patients Who Cannot Undergo Surgery,

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • PARTNER 3

    Partner 3: A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Requiring Aortic Valve Replacement who have Severe, Calcific, Symptomatic Aortic Stenosis

    Type: Device Trial

    Trial is open for enrollment.

    Prinicpal Investigator: Mark Russo, MD, MS

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • PORTICO

    St. Jude Medical, Cardiology Division, Inc. - PorticoTM Re-sheathable Transcatheter Aortic Valve System US IDE Trial

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • PIONEER AF-PCI

    Janssen Scientific Affairs, LLC - An open label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention.

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • A011104 / 6694

    Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer. The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Breast Care
    • Cancer
  • CK-SAPBI

    A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation. The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Breast Care
    • Cancer
  • NRG-BR003

    A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Breast Care
    • Cancer
Page of 9